Close

More on KYTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.6 Score)

Upcoming Events

- Earnings (2/28/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kyverna Therapeutics (NQ:KYTX)
Delayed: 3.60 +0.21 (6.19%)
Prev. Close $3.39  
Open$3.37 
52 Wk High$ 
52 Wk Low$ 
Day High$3.95 
Day Low$3.33 
P/E N/A  
EPS$ 
Volume2,873,548 

Friends, Peers and Foes (?): ADBE, ANF, CZR, RARE, TPR (more...)

Jan 24, 2025 08:05 PM Form 4 Kyverna Therapeutics, For: Jan 22 Filed by: GEHCHAN NAJI
Jan 24, 2025 08:00 PM Form 3 Kyverna Therapeutics, For: Jan 22 Filed by: GEHCHAN NAJI
Jan 23, 2025 11:06 PM ROSEN, NATIONAL TRIAL LAWYERS, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
Jan 23, 2025 03:17 PM KYTX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. (KYTX)
Jan 22, 2025 08:57 PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
Jan 21, 2025 04:07 PM Kyverna Therapeutics (KYTX) Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
Jan 21, 2025 04:06 PM Form 8-K Kyverna Therapeutics, For: Jan 21
Jan 21, 2025 04:05 PM Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
Jan 19, 2025 08:05 AM DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
Jan 18, 2025 04:16 PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
View All Articles

Entities mentioned with KYTX

View All Entities